Revvity (NYSE:RVTY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Revvity (NYSE:RVTY - Free Report) from a hold rating to a buy rating in a research report released on Saturday.

A number of other brokerages have also commented on RVTY. JPMorgan Chase & Co. cut their price objective on shares of Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. The Goldman Sachs Group dropped their target price on shares of Revvity from $140.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Robert W. Baird dropped their target price on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research report on Tuesday, April 29th. Raymond James Financial reissued an "outperform" rating and issued a $120.00 target price (down previously from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Finally, Barclays lowered their price objective on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.64.

Revvity Stock Down 1.0%

RVTY stock traded down $1.01 during trading on Friday, reaching $97.78. The stock had a trading volume of 1,331,016 shares, compared to its average volume of 968,598. Revvity has a 1-year low of $87.70 and a 1-year high of $129.50. The company has a current ratio of 3.58, a quick ratio of 2.99 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $11.53 billion, a P/E ratio of 41.61, a PEG ratio of 2.39 and a beta of 0.97. The firm has a fifty day moving average price of $93.36 and a 200 day moving average price of $105.37.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a net margin of 10.35% and a return on equity of 7.73%. The firm had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same quarter in the previous year, the business posted $0.98 EPS. The firm's revenue was up 2.3% compared to the same quarter last year. On average, equities analysts anticipate that Revvity will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date is Friday, July 18th. Revvity's payout ratio is 11.91%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RVTY. Sanctuary Advisors LLC acquired a new position in Revvity during the 4th quarter valued at about $209,000. Private Advisor Group LLC lifted its stake in shares of Revvity by 5.3% in the 4th quarter. Private Advisor Group LLC now owns 4,254 shares of the company's stock worth $475,000 after acquiring an additional 213 shares during the period. Ieq Capital LLC acquired a new stake in shares of Revvity in the 4th quarter worth approximately $223,000. Bank of New York Mellon Corp lifted its stake in shares of Revvity by 7.7% in the 4th quarter. Bank of New York Mellon Corp now owns 826,110 shares of the company's stock worth $92,202,000 after acquiring an additional 58,876 shares during the period. Finally, Proficio Capital Partners LLC lifted its stake in Revvity by 12,298.3% during the fourth quarter. Proficio Capital Partners LLC now owns 195,769 shares of the company's stock valued at $21,850,000 after purchasing an additional 194,190 shares during the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.